Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines

被引:8
作者
Liang, Weichen [1 ]
Liu, Jian [1 ]
Wu, Huazhang [2 ]
Qiao, Xuxu [3 ]
Lu, Xiang [1 ]
Liu, Yonghong [3 ]
Zhu, Hong [1 ]
Ma, Ling [1 ]
机构
[1] Bengbu Med Coll, Affiliated Hosp 1, Dept Gynecol Oncol, Bengbu 233030, Anhui, Peoples R China
[2] Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, Bengbu 233030, Anhui, Peoples R China
[3] Bengbu Med Coll, Grad Dept, Bengbu 233030, Anhui, Peoples R China
基金
中国国家自然科学基金;
关键词
epithelial-mesenchymal transition; ovarian cancer; artemisinin; celecoxib; SKOV3 cell line; EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER; IN-VIVO; METASTASIS; CELECOXIB; ACTIVATION; GROWTH; CHEMORESISTANCE; INVASION;
D O I
10.3892/ol.2019.10608
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Accumulating evidence suggests that celecoxib and artemisinin could mediate ovarian cancer development and metastasis. The present study investigated the effects of celecoxib and artemisinin on the epithelial-mesenchymal transition (EMT) characteristics of the human ovarian epithelial adenocarcinoma cell line, SKOV3. SKOV3 cells were incubated with celecoxib (10 mu M) for different periods of time to establish an EMT cell model. Subsequently, artemisinin (20, 40 and 80 mu M) was used to establish a cell model of the reverse process, mesenchymal-epithelial transition (MET). Cell proliferation, metastasis, invasiveness and the expression of vimentin and E-cadherin were measured using Cell Counting Kit-8, wound healing assay, western blotting, flow cytometry and immunofluorescence. The EMT cell model exhibited enhanced proliferative capacity, increased migration, increased vimentin expression and decreased E-cadherin expression. By contrast, artemisinin decreased proliferative capacity, decreased migration, decreased vimentin expression and increased E-cadherin expression of EMT model cells, indicating that MET was induced. These results demonstrated that artemisinin may reverse celecoxib-induced epithelial-mesenchymal transition in SKOV3 cells.
引用
收藏
页码:3407 / 3414
页数:8
相关论文
共 42 条
[1]   Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells [J].
Beccafico, Sara ;
Morozzi, Giulio ;
Marchetti, Maria Cristina ;
Riccardi, Carlo ;
Sidoni, Angelo ;
Donato, Rosario ;
Sorci, Guglielmo .
CARCINOGENESIS, 2015, 36 (09) :1071-1083
[2]   Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells [J].
Bocca, Claudia ;
Bozzo, Francesca ;
Cannito, Stefania ;
Parola, Maurizio ;
Miglietta, Antonella .
MOLECULAR CARCINOGENESIS, 2012, 51 (10) :783-795
[3]   Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma [J].
Bonneau, Claire ;
Rouzier, Roman ;
Geyl, Caroline ;
Cortez, Annie ;
Castela, Mathieu ;
Lis, Raphael ;
Darai, Emile ;
Touboul, Cyril .
GYNECOLOGIC ONCOLOGY, 2015, 136 (01) :112-120
[4]   Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1 [J].
Cha, Byong-Ki ;
Kim, Young-Suk ;
Hwang, Ki-Eun ;
Cho, Kyung-Hwa ;
Oh, Seon-Hee ;
Kim, Byoung-Ryun ;
Jun, Hong-Young ;
Yoon, Kwon-Ha ;
Jeong, Eun-Taik ;
Kim, Hak-Ryul .
ONCOTARGET, 2016, 7 (35) :57213-57227
[5]   Cancer incidence and mortality in China in 2013: an analysis based on urbanization level [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zhang, Siwei ;
Zeng, Hongmei ;
Zuo, Tingting ;
Xia, Changfa ;
Yang, Zhixun ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (01) :1-10
[6]   Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model [J].
Dong, Ji ;
Jiang, Dinghua ;
Wang, Zhen ;
Wu, Guizhong ;
Miao, Liyan ;
Huang, Lixin .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 441 (1-2) :285-290
[7]   Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways [J].
Fang, D. ;
Chen, H. ;
Zhu, J. Y. ;
Wang, W. ;
Teng, Y. ;
Ding, H-F ;
Jing, Q. ;
Su, S-B ;
Huang, S. .
ONCOGENE, 2017, 36 (11) :1546-1558
[8]   Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis [J].
Jeong, Da Eun ;
Song, Hye Jin ;
Lim, Sharon ;
Lee, Se Jeong ;
Lim, Joung Eun ;
Nam, Do-Hyun ;
Joo, Kyeung Min ;
Jeong, Byong Chang ;
Jeon, Seong Soo ;
Choi, Han Yong ;
Lee, Hye Won .
ONCOTARGET, 2015, 6 (32) :33046-33064
[9]   Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer [J].
Kreuzinger, Caroline ;
Gamperl, Magdalena ;
Wolf, Andrea ;
Heinze, Georg ;
Geroldinger, Angelika ;
Lambrechts, Diether ;
Boeckx, Bram ;
Smeets, Dominiek ;
Horvat, Reinhard ;
Aust, Stefanie ;
Hamilton, Gerhard ;
Zeillinger, Robert ;
Castillo-Tong, Dan Cacsire .
CANCER LETTERS, 2015, 362 (02) :218-228
[10]   Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process [J].
Lee, Hae-Miru ;
Hwang, Kyung-A ;
Choi, Kyung-Chul .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 457 (0C) :103-113